Vittorio Grosso, Francisca Bulai, Alice Cerato, Cristina Olivero, Irene Praticò, Eleonora Galli, Francesca Diana, Matteo Nicoletto, Alberto Grosso, Luigi La Via, Fulvio Pomero
{"title":"The Role of Anti-MDA5 Antibodies in Rapidly Progressive Interstitial Lung Disease: A Case Report and Literature Review.","authors":"Vittorio Grosso, Francisca Bulai, Alice Cerato, Cristina Olivero, Irene Praticò, Eleonora Galli, Francesca Diana, Matteo Nicoletto, Alberto Grosso, Luigi La Via, Fulvio Pomero","doi":"10.2174/0115748871350269250507052714","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Anti-melanoma Differentiation-associated Gene 5 (aMDA5) antibody-associated Rapidly Progressive Interstitial Lung Disease (RP-ILD) is a rare and potentially fatal condition.</p><p><strong>Case presentation: </strong>This case report describes a 78-year-old male who presented with a 10-day history of fever, cough, and asthenia. Despite initial treatment for suspected atypical pneumonia, the clinical condition rapidly deteriorated, necessitating intensive care and mechanical ventilation. High-resolution CT scans revealed a progressive interstitial lung disease with pneumomediastinum. Autoimmunity blood tests revealed high-titer anti-MDA5 antibodies bringing to a diagnosis of anti-MDA5 RP-ILD. Despite aggressive immunosuppressive therapy, the patient's condition continued to worsen, resulting in death. Our case underlines the importance of early recognition and diagnosis of anti-MDA5 RP-ILD, as it can present without typical dermatomyositis skin manifestations. The report also includes a comprehensive literature review covering the pathogenesis, clinical manifestations, diagnosis, and treatment options for anti-MDA5-associated disease.</p><p><strong>Conclusion: </strong>This case underscores the need for increased awareness of this condition among clinicians to improve early diagnosis and treatment outcomes.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews on recent clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748871350269250507052714","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Anti-melanoma Differentiation-associated Gene 5 (aMDA5) antibody-associated Rapidly Progressive Interstitial Lung Disease (RP-ILD) is a rare and potentially fatal condition.
Case presentation: This case report describes a 78-year-old male who presented with a 10-day history of fever, cough, and asthenia. Despite initial treatment for suspected atypical pneumonia, the clinical condition rapidly deteriorated, necessitating intensive care and mechanical ventilation. High-resolution CT scans revealed a progressive interstitial lung disease with pneumomediastinum. Autoimmunity blood tests revealed high-titer anti-MDA5 antibodies bringing to a diagnosis of anti-MDA5 RP-ILD. Despite aggressive immunosuppressive therapy, the patient's condition continued to worsen, resulting in death. Our case underlines the importance of early recognition and diagnosis of anti-MDA5 RP-ILD, as it can present without typical dermatomyositis skin manifestations. The report also includes a comprehensive literature review covering the pathogenesis, clinical manifestations, diagnosis, and treatment options for anti-MDA5-associated disease.
Conclusion: This case underscores the need for increased awareness of this condition among clinicians to improve early diagnosis and treatment outcomes.
期刊介绍:
Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal"s aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I – IV clinical trial studies, clinical investigations at all stages of development and therapeutics. The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.